Serum and cerebrospinal fluid heavy neurofilaments and antibodies against them in early multiple sclerosis

Journal of Neuroimmunology

Volumn 259, Issue 1-2, 2013, Pages 81-87

  Fialová, Lenka ^a   Bartos, Ales ^b,c   Švarcová, Jana ^a   Zimova, Denisa ^c   Kotoucova, Jolana ^c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Antibody; Cerebrospinal fluid; Clinically isolated syndrome; Heavy neurofilament; Multiple sclerosis; Serum

Indexed keywords

BIOLOGICAL MARKER; HEAVY NEUROFILAMENT PROTEIN; HEAVY NEUROFILAMENT PROTEIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; NEUROFILAMENT PROTEIN; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NERVE CELL LESION; NEUROIMMUNOLOGY; NEUROPATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN SECRETION; UPREGULATION;

ADULT; AUTOANTIBODIES; EARLY DIAGNOSIS; FEMALE; HUMANS; IMMUNOGLOBULIN G; LONGITUDINAL STUDIES; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROFILAMENT PROTEINS; PROGNOSIS; PROSPECTIVE STUDIES; SEROEPIDEMIOLOGIC STUDIES; YOUNG ADULT;

EID: 84877630368     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.03.009     Document Type: Article

References (51)

1. Awad A., Hemmer B., Hartung H.P., Kieseier B., Bennett J.L., Stuve O. Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. J. Neuroimmunol. 2010, 219:1-7.
2. Bartos A., Fialova L., Soukupova J., Kukal J., Malbohan I., Pit'ha J. Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis. J. Neurol. 2007, 254:20-25.
3. Bartos A., Fialova L., Soukupova J., Kukal J., Malbohan I., Pitha J. Antibodies against light neurofilaments in multiple sclerosis patients. Acta Neurol. Scand. 2007, 116:100-107.
4. Bartos A., Fialova L., Svarcova J., Ripova D. Patients with Alzheimer disease have elevated intrathecal synthesis of antibodies against tau protein and heavy neurofilament. J. Neuroimmunol. 2012, 252:100-105.
5. Beltran E., Hernandez A., Lafuente E.M., Coret F., Simo-Castello M., Bosca I., Perez-Miralles F.C., Burgal M., Casanova B. Neuronal antigens recognized by cerebrospinal fluid IgM in multiple sclerosis. J. Neuroimmunol. 2012, 247:63-69.
6. Brettschneider J., Petzold A., Junker A., Tumani H. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Mult. Scler. 2006, 12:143-148.
7. Bruck W. The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J. Neurol. 2005, 252(Suppl. 5):v3-v9.
8. Deisenhammer F., Bartos A., Egg R., Gilhus N.E., Giovannoni G., Rauer S., Sellebjerg F. Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force. Eur. J. Neurol. 2006, 13:913-922.
9. Delpech B., Lichtblau E. Immunochemical estimation of IgG and albumin in cerebrospinal fluid. Clin. Chim. Acta 1972, 37:15-23.
10. Disanto G., Morahan J.M., Barnett M.H., Giovannoni G., Ramagopalan S.V. The evidence for a role of B cells in multiple sclerosis. Neurology 2012, 78:823-832.
11. Ehling R., Lutterotti A., Wanschitz J., Khalil M., Gneiss C., Deisenhammer F., Reindl M., Berger T. Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis. Mult. Scler. 2004, 10:601-606.
12. Eikelenboom M.J., Petzold A., Lazeron R.H., Silber E., Sharief M., Thompson E.J., Barkhof F., Giovannoni G., Polman C.H., Uitdehaag B.M. Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology 2003, 60:219-223.
13. Eikelenboom M.J., Uitdehaag B.M., Petzold A. Blood and CSF biomarker dynamics in multiple sclerosis: implications for data interpretation. Mult. Scler. Int. 2011, 2011:823176.
14. Fialova L., Bartos A., Svarcova J., Malbohan I. Increased intrathecal high-avidity anti-tau antibodies in patients with multiple sclerosis. PLoS One 2011, 6:e27476.
15. Fialová L., Bartos A., Švarcová J., Malbohan I. Tau protein and anti-Tau antibodies in patients with multiple sclerosis. Cesk. Slov. Neurol. N. 2012, 75(108):310-313.
16. Giovannoni G. Cerebrospinal fluid neurofilament: the biomarker that will resuscitate the 'Spinal Tap'. Mult. Scler. 2010, 16:285-286.
17. Huizinga R., Heijmans N., Schubert P., Gschmeissner S., t Hart B.A., Herrmann H., Amor S. Immunization with neurofilament light protein induces spastic paresis and axonal degeneration in Biozzi ABH mice. J. Neuropathol. Exp. Neurol. 2007, 66:295-304.
18. Huizinga R., Linington C., Amor S. Resistance is futile: antineuronal autoimmunity in multiple sclerosis. Trends Immunol. 2008, 29:54-60.
19. Johnston K.M., Connolly J.A., van der Kooy D. Inhibition of axonal transport 'in vivo' by a tubulin-specific antibody. Brain Res. 1986, 385:38-45.
20. Khalil M., Enzinger C., Langkammer C., Ropele S., Mader A., Trentini A., Vane M., Wallner-Blazek M., Bachmaier G., Archelos J.J., Koel-Simmelink M., Blankenstein M., Fuchs S., Fazekas F., Teunissen C. CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome. Mult. Scler. 2012, 10.1177/1352458512458010.
21. Klawiter E.C., Piccio L., Lyons J.A., Mikesell R., O'Connor K.C., Cross A.H. Elevated intrathecal myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis. Arch. Neurol. 2010, 67:1102-1108.
22. Kuhle J., Regeniter A., Leppert D., Mehling M., Kappos L., Lindberg R.L., Petzold A. A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein. J. Neuroimmunol. 2010, 220:114-119.
23. Kuhle J., Leppert D., Petzold A., Regeniter A., Schindler C., Mehling M., Anthony D.C., Kappos L., Lindberg R.L. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology 2011, 76:1206-1213.
24. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
25. Lassmann H. Axonal and neuronal pathology in multiple sclerosis: what have we learnt from animal models. Exp. Neurol. 2010, 225:2-8.
26. Lim E.T., Sellebjerg F., Jensen C.V., Altmann D.R., Grant D., Keir G., Thompson E.J., Giovannoni G. Acute axonal damage predicts clinical outcome in patients with multiple sclerosis. Mult. Scler. 2005, 11:532-536.
27. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996, 46:907-911.
28. Malmestrom C., Haghighi S., Rosengren L., Andersen O., Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003, 61:1720-1725.
29. Meinl E., Krumbholz M., Hohlfeld R. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann. Neurol. 2006, 59:880-892.
30. Peterson L.K., Fujinami R.S. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis. J. Neuroimmunol. 2007, 184:37-44.
31. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J. Neurol. Sci. 2005, 233:183-198.
32. Petzold A., Brassat D., Mas P., Rejdak K., Keir G., Giovannoni G., Thompson E.J., Clanet M. Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis. Mult. Scler. 2004, 10:281-283.
33. Petzold A., Eikelenboom M.J., Keir G., Grant D., Lazeron R.H., Polman C.H., Uitdehaag B.M., Thompson E.J., Giovannoni G. Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. J. Neurol. Neurosurg. Psychiatry 2005, 76:206-211.
34. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L., Lublin F.D., Metz L.M., McFarland H.F., O'Connor P.W., Sandberg-Wollheim M., Thompson A.J., Weinshenker B.G., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol. 2005, 58:840-846.
35. Reindl M., Khalil M., Berger T. Antibodies as biological markers for pathophysiological processes in MS. J. Neuroimmunol. 2006, 180:50-62.
36. Rejdak K., Petzold A., Stelmasiak Z., Giovannoni G. Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis. Mult. Scler. 2008, 14:59-66.
37. Sadaba M.C., Tzartos J., Paino C., Garcia-Villanueva M., Alvarez-Cermeno J.C., Villar L.M., Esiri M.M. Axonal and oligodendrocyte-localized IgM and IgG deposits in MS lesions. J. Neuroimmunol. 2012, 247:86-94.
38. Semra Y.K., Seidi O.A., Sharief M.K. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J. Neuroimmunol. 2002, 122:132-139.
39. Silber E., Semra Y.K., Gregson N.A., Sharief M.K. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology 2002, 58:1372-1381.
40. Soussan L., Tchernakov K., Bachar-Lavi O., Yuvan T., Wertman E., Michaelson D.M. Antibodies to different isoforms of the heavy neurofilament protein (NF-H) in normal aging and Alzheimer's disease. Mol. Neurobiol. 1994, 9:83-91.
41. Stefansson K., Marton L.S., Dieperink M.E., Molnar G.K., Schlaepfer W.W., Helgason C.M. Circulating autoantibodies to the 200,000-dalton protein of neurofilaments in the serum of healthy individuals. Science 1985, 228:1117-1119.
42. Svarcova J., Fialova L., Bartos A., Steinbachova M., Malbohan I. Cerebrospinal fluid antibodies to tubulin are elevated in the patients with multiple sclerosis. Eur. J. Neurol. 2008, 15:1173-1179.
43. Talja I., Reimand T., Uibo O., Reimand K., Aun S., Talvik T., Janmey P.A., Uibo R. Antibodies to neurofilaments. Ann. N. Y. Acad. Sci. 2009, 1173:130-136.
44. Terryberry J.W., Thor G., Peter J.B. Autoantibodies in neurodegenerative diseases: antigen-specific frequencies and intrathecal analysis. Neurobiol. Aging 1998, 19:205-216.
45. Teunissen C.E., Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Mult. Scler. 2012, 18:552-556.
46. Teunissen C.E., Dijkstra C., Polman C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol. 2005, 4:32-41.
47. Teunissen C.E., Iacobaeus E., Khademi M., Brundin L., Norgren N., Koel-Simmelink M.J., Schepens M., Bouwman F., Twaalfhoven H.A., Blom H.J., Jakobs C., Dijkstra C.D. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology 2009, 72:1322-1329.
48. Teunissen C.E., Petzold A., Bennett J.L., Berven F.S., Brundin L., Comabella M., Franciotta D., Frederiksen J.L., Fleming J.O., Furlan R., Hintzen R.Q., Hughes S.G., Johnson M.H., Krasulova E., Kuhle J., Magnone M.C., Rajda C., Rejdak K., Schmidt H.K., van Pesch V., Waubant E., Wolf C., Giovannoni G., Hemmer B., Tumani H., Deisenhammer F. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009, 73:1914-1922.
49. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mork S., Bo L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998, 338:278-285.
50. Tumani H., Hartung H.P., Hemmer B., Teunissen C., Deisenhammer F., Giovannoni G., Zettl U.K. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol. Dis. 2009, 35:117-127.
51. Vyshkina T., Kalman B. Autoantibodies and neurodegeneration in multiple sclerosis. Lab. Invest. 2008, 88:796-807.